Lead Sponsor

Bayer

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients who are confirmed to have 1-5 metastatic brain tumor by the latest contrast-enhanced cerebral CT or contrast-enhanced cerebral MRI, and the lesion(s) have not been treated by surgery or by stereotactic radiosurgery.

•Patients who are scheduled to receive another contrast medium for MRI (except for oral agents) or iodine contrast medium (except for oral agents), or to undergo surgical procedures during the period from the day before administration of Magnevist (SH L 451A) to examination of safety on the following day.
•Patients who underwent or are scheduled to undergo radiotherapy during the period from 14 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.
•Patients who were treated or are scheduled to be treated with anti-cancer agents (except for treatment only by the oral agents of the fixed dose continuously from 28 days or more before administration of Magnevist (SH L 451A)) during the period from 28 days before administration of Magnevist (SH L 451A) to examination of safety on the following day.

Related studies

NCT05386108 · Breast Neoplasms, Brain Neoplasms, and more

NCT06930846 · Brain Cancer, Brain Tumor, and more

NCT01638130 · Brain Neoplasms, Primary Malignant

NCT05267158 · Brain Metastases, Adult, Brain Neoplasms, Adult, Malignant

NCT07238322 · Retrospective Study, Glioma, and more

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis